AMGN Related Analyst Ratings
-
Analyst Sees Amgen's (AMGN) Dmab Delay Opening a Buying Window
-
UBS Upgrades Amgen (AMGN) to Buy
-
BofA/Merrill Restarts Gilead at Buy; Amgen, Celgene at Neutral; Biogen at Underperform (GILD, AMGN, CELG, BIIB)
-
Citi Downgrades Amgen (AMGN) to Hold
-
RBC Capital Starts Amgen (AMGN) at Outperform
-
Baird Reiterates an 'Outperform' on Amgen (AMGN); Raises Estimates
-
Piper Jaffray Reiterates an 'Overweight' on Regeneron Pharmaceuticals (REGN); Raises Price Target
-
Baird Boosts Price Target on Amgen (AMGN) to $65 on Dmab News
-
Bernstein Upgrades Amgen (AMGN) to Outperform
-
Barclays Gets Bullish On US Biotechnology Sector (BBH)
-
Wachovia Resumes Coverage on Amgen (AMGN) with an Outperform; Valuation Range $61-65
-
Baird Upgrades Amgen (AMGN) To Outperform
-
FTN Equity Starts Genzyme (GENZ) at Buy, Gilead (GILD), Amgen (AMGN) at Neutral
-
Baird Reiterates a 'Neutral' Rating on Amgen (AMGN); Lowers Estimates & Price Target
-
JP Morgan Upgrades Amgen (AMGN) to Overweight
-
Citi Reiterates a 'Buy' Rating on Teva Pharmaceutical (TEVA)
-
Goldman Sachs Removed Amgen (AMGN) from its Conviction Buy List
-
Citi Maintains 'Buy' Rating on Amgen (AMGN), Adds Stock to Top Picks Live List
-
Benchmark Capital Upgrades Maxygen (MAXY) to Buy
-
William Blair Upgrades Amgen (AMGN) to Outperform
-
Leerink Swann Starts Amgen (AMGN) at Outperform
-
Amgen (AMGN) volatility Flat on sharp two-month rally; Goldman Adds To Buy List
-
Goldman Sachs Added Amgen (AMGN) to its Conviction Buy List
-
Banc of America Starts Amgen (AMGN) at Buy
-
Citi Upgrades Amgen (AMGN) to Buy
-
Merrill Lynch Upgrades Amgen (AMGN) to Buy
-
Morgan Joseph Starts Amgen (AMGN) at Buy
-
Deutsche Bank Raises Their Price Target on Amgen (AMGN) to $73
-
Jefferies & Co. Upgrades Amgen (AMGN) to Buy
-
Rodman & Renshaw Upgrades Amgen (AMGN) to Market Outperform
-
Morgan Stanley Upgrades Amgen (AMGN) to Overweight
-
Deutsche Bank Comments on Recent Strength in Amgen (AMGN), Cites Positive Buy-Side Meetings
-
Deutsche Bank Starts Amgen (AMGN) At Buy, Citing Appealing Risk/Reward
-
Deutsche Bank Starts Coverage on Large Biotechs; DNA, GILD & AMGN Rated Buys, BIIB & GENZ Rated Holds
-
Wachovia Downgrades Amgen (AMGN) to Market Perform
-
Citi Maintains 'Hold' Rating on Amgen (AMGN), Comments on FDA Briefing Documents
-
Citi Analyst Comments on Court Decision Between Amgen (AMGN) and Roche
-
S&P Equity Research downgrades Amgen (AMGN) to Hold
-
Lazard upgrades Amgen (AMGN) to Hold
-
Merrill Lynch Downgrades Amgen (AMGN) to Neutral
-
Bernstein Downgrades Amgen (AMGN) to Market Perform
-
Lehman Brothers upgrades Amgen (AMGN) to Overweight
-
Credit Suisse upgrades Amgen (AMGN) to Outperform
-
Analyst Sees Biogen and ImClone as Likely M&A Targets and To a Lesser Extent Genzyme
-
BusinessWeek's Inside Wall Street Highlights (AMGN, MAIL, OIIM)
-
Stifel Nicolaus downgrades Amgen (AMGN) to Hold
-
Merrill Lynch upgrades Amgen (AMGN) to Buy
-
UBS upgrades Amgen (AMGN) to Neutral
-
Bernstein Upgrades Amgen (AMGN) to Outperform
-
Citigroup Upgrades Amgen (AMGN) to Hold
Back to AMGN Stock Lookup
